BioCentriq Invests US$12 million to Expand Cell Therapy Manufacturing Facility in USA
Introduction:
BioCentriq palns to invest a state-of-the-art cell therapy manufacturing facility in New Jersey, USA.
Features:
The 60,000 square feet facility houses six (6) cutting-edge ISO 7 cleanrooms, equipped with modern bioreactors, automated cell processing technologies, and scalable manufacturing systems.
With an established expertise in cell therapy manufacturing, the site operates under current GMP regulatory standards and industry best practises. It also offers 30,000 square feet of additional space to support future clinical and commercial scale production needs.
The expansion includes an immediate US$12 million capital investment in facility upgrades, advanced equipment, and enhanced business systems. These improvements will strengthen in the fast-growing cell therapy sector while expanding its ability to provide end-to-end development, manufacturing, and quality control services throughout the product lifecycle.
The facility features two (2) ISO 7 cleanrooms, an integrated quality control laboratory, and extensive support infrastructure. It will continue serving as both a clinical GMP production centre and a hub for specialised training and workforce development for pharmaceutical and biotech innovators and service providers.
The new facility is expected to be completed and fully operational by Q2 2025, with manufacturing services available shortly thereafter.
Specifications:
| Name : | BioCentriq |
| Type : | New Construction |
| Budget : | US$12 million |
| Year : | 2025 |
